Publications

5891 Results

Summary and recommendations from the National Cancer Institute's Clinical Trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer

Authors
SP Lerner;DF Bajorin;CP Dinney;JA Efstathiou;S Groshen;NM Hahn;D Hansel;D Kwiatkowski;M O'Donnell;J Rosenberg;R Svatek;JS Abrams;H Al-Ahmadie;AB Apolo;J Bellmunt;M Callahan;EK Cha;C Drake;J Jarow;A Kamat;W Kim;M Knowles;B Mann;L Marchionni;D McConkey;L McShane;N Ramirez;A Sharabi;AH Sharpe;D Solit;CM Tangen;AT Amiri;E Van Allen;PJ West;JA Witjes;D Quale
Journal / Conference
Bladder Cancer Apr 27;2(2):165-202
Year
2016
Research Committee(s)
Genitourinary
PMID
PMID27376138
PMC
PMC4927845
Study Number(s)
S0337, S0353, S1314, S1602, SWOG-8507

A pooled analysis of glycemic index and load and prostate cancer risk

Authors
E Sidahmed;SJ Freedland;M Wang;K Wu;JM Genkinger;SA Smith-Warner
Journal / Conference
American Institute for Cancer Research (Nov 14-16, Bethesda, MD), poster
Year
2016
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
Study Number(s)
SWOG-9217

Autotransplants should be offered early for Waldentrom macroglobulinenia (WM)

Authors
B Barlogie;K Chansky;A Hoering;J Crowley;M Dhodapkar
Journal / Conference
International Workshop for Waldenstrom's Macroglobulinemia (IWWM-9) (October 5-8, 2016, Amsterdam, Netherlands), LBA, oral, invited talk, session 15
Year
2016
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9003, S9805

Disease and outcome disparities in multiple myeloma (MM): exploring the role of race/ethnicity and obesity in Cooperative Group Clinical Trials

Authors
S Ailawadhi;S Jacobus;R Sexton;AK Stewart;A Dispenzieri;MA Hussein;J Zonder;J Crowley;A Hoering;B Barlogie;R Orlowski;SV Rajkumar
Journal / Conference
Blood 128:1192; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Cancer Survivorship and Myeloma
Study Number(s)
S0204, S0232, SWOG-9321

Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large b-cell lymphoma: (Alliance) CALGB 50303

Authors
WH Wilson;S-H Jung;B Pitcher;E Hsi;RI Fisher;B Cheson;N Bartlett;S Smith;NW Johnston;B Kahl;L Staudt;K Blum;J Abramson;O Press;JW Friedberg;A Zelenetz;JP Leonard
Journal / Conference
Blood 128:469; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Lymphoma

Serum biomarkers predict outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Authors
JA Kanakry;F Hong;O Martinez-Maza;SJ Horning;LI Gordon;RD Gascoyne;LL Gellert;M Lemas;B Cheson;R Advani;B Pohlman;L Teston;VP Kenkre;JN Winter;P Stiff;J Tuscano;JW Friedberg;J Polikoff;LM Dreosti;JP Kuebler;S Robinson;DS Morgan;RI Fisher;N Bartlett;P Laneuville;B Kahl;RF Ambinder
Journal / Conference
Blood 128:2992; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Lymphoma
Study Number(s)
E2496

A Phase 1/2 Study of G-CSF, cladribine, cytarabine, and dose-escalated mitoxantrone (G-CLAM) in adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS): final results from a phase 1/2 study

Authors
A Halpern;E Estey;EM Huebner;M Othus;KF Orlowski;BL Scott;HA Smith;PS Becker;M-B M Percival;PC Hendrie;AM Perdue;T Chen;S Buckley;H Erba;R Walter
Journal / Conference
Blood 128:1068; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106

SWOG S1203: A randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML)

Authors
G Garcia-Manero;M Othus;J Pagel;J Radich;M Fang;DA Rizzieri;G Marcucci;S Strickland;MR Litzow;ML Savoie;B Medeiros;M Sekeres;T Lin;G Uy;BL Powell;J Kolitz;R Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;FR Appelbaum;H Erba
Journal / Conference
Blood 128:901; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1203

Feasibility of allogeneic hematopoietic cell transplantation among high-risk AML patients in first complete remission: results of the transplant objective from the SWOG (S1203) randomized phase III study of induction therapy using standard 7+3 therapy or idarubicin with high-dose cytarabine (IA) versus IA plus vorinostat

Authors
J Pagel;G Garcia-Manero;M Fang;J Radich;DA Rizzieri;G Marcucci;S Strickland;MR Litzow;ML Savoie;S Spellman;D Confer;J Chell;M Brown;B Medeiros;M Sekeres;TL Lin;G Uy;BL Powell;J Kolitz;RA Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;H Erba;F Appelbaum
Journal / Conference
Blood 128:1166; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1203

A Phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed/ refractory CD22+ acute leukemia (SWOG 1312) [ http://www.bloodjournal.org/content/128/22/1634]

Authors
A Advani;A Moseley;M Liedtke;M O'Donnell;M Othus;M Mims;K O'Dwyer;H Erba
Journal / Conference
Blood 128:1634; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1312